The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells Fatemeh SafariSetareh BararpourFatemeh Omidi Chomachaei Research 27 March 2024
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer Tomoki HoriKazuhiro YamamotoIkuko Yano Research Open access 27 March 2024
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer Noboru YamamotoMiyako SatouchiMakoto Nishio Research Open access 26 March 2024
Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients Kazuma FujitaDaiki TaguchiMasatomo Miura Research Open access 22 March 2024
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors Maxime Chénard-PoirierAaron R. HansenManish R. Sharma Research Open access 14 March 2024
Learn more about Springer Nature’s oncology titles Discover the range of academic oncology titles at Springer Nature here.